MedPath

Tagged News

Tempus AI Raises $650 Million Through Convertible Notes to Advance AI-Driven Precision Medicine Platform

AIPrecision Medicine
  • Tempus AI successfully priced a $650 million convertible senior notes offering, increasing from the initially announced $400 million, to fund its AI-enabled precision medicine platform development.
  • The company plans to use approximately $274.7 million of proceeds to repay existing debt and $36.2 million for capped call transactions, with remaining funds allocated to general corporate purposes including potential acquisitions.
  • The notes carry a 0.75% annual interest rate and mature in 2030, with conversion features that allow holders to convert to Tempus Class A common stock at approximately $84.19 per share.
  • Tempus operates one of the world's largest multimodal healthcare data libraries and provides AI-powered precision medicine solutions to physicians for personalized patient care and therapeutic development.

LogicFlo AI Secures $2.7M to Deploy AI Agents Across Life Sciences Operations

AI
  • LogicFlo AI raised $2.7 million in seed funding led by Lightspeed to expand its AI agent platform across pharmaceutical, biotech, and medtech organizations globally.
  • The platform has demonstrated significant productivity gains in early deployments, reducing medical writing timelines from weeks to minutes and cutting medical information response times from two weeks to two days.
  • Founded by former Abbott executive Udith Vaidyanathan and ex-Intuitive Surgical AI lead Arun Ramakrishnan, the company focuses on human-guided AI automation for regulated scientific work.
  • The funding will support product development, deeper integrations with life sciences systems like Veeva and IQVIA, and team expansion to meet growing industry demand.

FDA Grants Breakthrough Device Designation to TOBY's AI-Powered Urine Test for Bladder Cancer Detection

AI
  • TOBY, Inc. received FDA Breakthrough Device Designation for its non-invasive urine-based test that detects bladder cancer using volatile organic compounds and artificial intelligence technology.
  • The TOBY Test analyzes VOCs in urine samples through gas chromatography-mass spectrometry and proprietary AI to generate real-time cancer risk scores as an alternative to invasive cystoscopy procedures.
  • Bladder cancer ranks as the sixth most common cancer in the U.S. but remains one of the costliest to manage due to high recurrence rates and reliance on invasive surveillance methods.
  • The company is preparing multi-cancer clinical studies to validate its platform's ability to detect more than ten cancers from a single sample, potentially covering over 60% of global cancer cases.

Spectral AI Submits De Novo FDA Application for AI-Powered Burn Assessment Device

AI
  • Spectral AI has submitted a De Novo 510k marketing clearance application to the FDA for its DeepView System, an AI-driven device that predicts burn healing potential using multispectral imaging.
  • The DeepView System provides clinicians with non-healing predictions on the same day of injury and up to seven days post-injury, enabling earlier treatment decisions in burn centers and emergency departments.
  • The device received FDA Breakthrough Device Designation in 2018 and represents a novel technology without existing predicate devices in the U.S. market.
  • Development has been supported by federal funding from BARDA under multiple contracts since 2013, highlighting government investment in advanced burn care diagnostics.

Portal Biotech Secures $35M Series A to Commercialize World's First Full-Length Single-Molecule Protein Sequencer

Drug DiscoveryAI
  • Portal Biotech raised $35 million in Series A funding, representing one of Europe's largest investments into a life sciences tools company, co-led by NATO Innovation Fund and Earlybird Venture Capital.
  • The London-based company is developing the world's first technology for sequencing intact full-length proteins at the single-molecule level, addressing critical gaps in current protein analysis methods.
  • The nanopore-based platform promises to transform drug discovery and diagnostics by providing rapid, cost-effective protein characterization that could prevent billions in failed drug trials.
  • The technology aims to replace expensive mass spectrometry methods with accessible desktop instruments, making advanced protein analysis available to any laboratory worldwide.

AI Model NeoPred Predicts Lung Cancer Treatment Response Before Surgery Using Dual-Phase CT Imaging

AI
  • Researchers at Guangzhou Medical University developed NeoPred, an AI model that uses dual-phase CT scans and clinical data to predict major pathological response to neoadjuvant chemo-immunotherapy in NSCLC patients before surgery.
  • The model achieved an AUC of 0.787 in external validation and outperformed expert thoracic surgeons in prospective testing, with surgeons' accuracy improving to 82% when using AI assistance.
  • NeoPred successfully identified treatment responders among patients classified as "stable disease" by traditional imaging criteria, achieving AUCs of 0.742-0.833 in detecting these "pseudo-stable" responders.
  • The breakthrough enables clinicians to make evidence-based treatment decisions 1-2 weeks before surgery, potentially optimizing perioperative management and personalized treatment planning for lung cancer patients.

FDA Clears Siemens Healthineers' First Virtually Helium-Free 1.5T MRI Scanner

AI
  • The FDA has granted 510(k) clearance for Siemens Healthineers' Magnetom Flow.Ace MRI scanner, which requires only 0.7 liters of liquid helium compared to over 1,000 liters in conventional systems.
  • The system features a closed helium circuit with no quench pipe and reduces annual energy consumption by more than 30% compared to previous generation scanners.
  • The 60 cm bore scanner incorporates AI-powered image reconstruction technology and is designed for both human and veterinary applications.
  • The compact design and elimination of the quench pipe facilitate easier installation and reduce costs compared to other 1.5T MR scanners.

Cellarity Initiates Phase 1 Trial of CLY-124, First-in-Class Oral Therapy for Sickle Cell Disease

AIRare Disease
  • Cellarity has dosed the first patient in a Phase 1 clinical trial of CLY-124, a novel oral medicine that increases fetal hemoglobin through a globin-switching mechanism to treat sickle cell disease.
  • The drug was discovered using AI-powered transcriptomic analysis and demonstrated the ability to increase fetal hemoglobin above 20% in preclinical studies without cytotoxicity.
  • CLY-124 represents a potential breakthrough for sickle cell disease treatment, offering a once-daily oral alternative to current therapies that carry dose-limiting toxicity.
  • The Phase 1 global trial will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers before advancing to sickle cell disease patients.

Invetech and AiCella Form Strategic Partnership to Integrate AI into Cell Therapy Manufacturing

AI
  • Invetech and AiCella announced a strategic collaboration to combine custom automation expertise with artificial intelligence to optimize cell therapy production processes and maximize patient treatment responses.
  • The partnership aims to help therapy developers identify critical process parameters earlier, reduce manufacturing variability, and accelerate the development of scalable, patient-ready therapies.
  • AiCella's AI platform will be embedded directly into the development and manufacturing lifecycle to generate data-driven insights about which parameters most influence therapeutic efficacy.
  • The collaboration targets the $10B+ cell therapy manufacturing market by integrating real-world process and clinical data with advanced machine learning models.

£7.5 Million Longitude Prize Launches to Accelerate AI-Driven ALS Drug Discovery

AIDrug Discovery
  • The Longitude Prize on ALS has launched as a £7.5 million global challenge to incentivize AI-based approaches for drug discovery targeting amyotrophic lateral sclerosis, the most common form of motor neurone disease.
  • The competition will provide access to the largest collection of ALS patient data ever assembled, with 20 initial winners receiving £100,000 each in 2026 and a final £1 million grand prize awarded in 2031.
  • The prize is principally funded by the Motor Neurone Disease Association and aims to identify promising drug targets for a disease that currently has no long-term treatments or cure.
  • Teams will progress through multiple stages of validation, with the ultimate goal of identifying therapeutic targets with the strongest evidence of potential for treating ALS patients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.